Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
A phase 1/2 trial of PRGN-2012 - Phase I; Dose Level 1 in rare cancers of childhood, run by Precigen, Inc, active and no longer recruiting.
Overview
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis is a phase 1/2 interventional study registered as NCT04724980 by Precigen, Inc, with 38 participants enrolled, started 2021-03-16 and due to reach its primary completion in 2024-06-05. Interventions recorded: PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2 and PRGN-2012 - Phase II; Dose Level 2.
Setting
A Phase 1/2 Study of Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Phase
Phase 1/2
Sponsor
Precigen, Inc
Registry
Enrolled
38
Similar pages
not linked directly; found by shared links- TreatmentTQ-B3234
Shares Rare cancers of childhood (NCI PDQ umbrella) and the tag pipeline.